Trial Profile
Safety and Efficacy of L. Reuteri ATCC PTA 5289 & L. Reuteri DSM 17938 in Pregnant Women to Improve Oral Health and Reduce the Risk for Prematurity or Intrauterine Growth Retardation (IUGR)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Jul 2021
Price :
$35
*
At a glance
- Drugs Limosilactobacillus reuteri (Primary)
- Indications Periodontal disorders
- Focus Therapeutic Use
- 05 Jul 2021 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified June 2019).
- 27 Jul 2019 Planned End Date changed from 30 Nov 2018 to 30 Dec 2019.
- 27 Jul 2019 Status changed from not yet recruiting to recruiting.